Good to cinfirm that both Coviu and Phenix automatically prompt patients to access Resapp if they have respiratory symptoms (ie its not up to the doctor to suggest it) and that our cut is the target range of $5-$10 a share. Should keep those downrampers saying 'we'll be lucky to keep $1, quiet!
Ann: Quarterly Results and Investor Conference Call Notification, page-225
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #
-
- There are more pages in this discussion • 72 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)